Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52‐week randomized controlled clinical trial
GLP-1 analogue
Adult
Glycated Hemoglobin
Blood Glucose
liraglutide
clinical trial
Liraglutide
Overweight
Incretins
3. Good health
Prediabetic State
Diabetes, Gestational
Glucose
Treatment Outcome
Diabetes Mellitus, Type 2
Double-Blind Method
Pregnancy
Humans
Hypoglycemic Agents
incretin therapy
Female
Obesity
GLP-1
DOI:
10.1111/dom.15306
Publication Date:
2023-10-17T08:37:20Z
AUTHORS (14)
ABSTRACT
We investigated the effect of 52-week treatment with liraglutide, a glucagon-like peptide 1 receptor agonist, on glucose tolerance and incretin in women previous gestational diabetes mellitus (pGDM).Women overweight/obesity pGDM were randomized to once daily subcutaneous liraglutide 1.8 mg or placebo for 52 weeks. Participants underwent oral test (OGTT) isoglycaemic intravenous infusion at baseline weeks, an additional OGTT after drug wash-out.In total, 104 [age: mean ± SD, 38 5 years; fasting plasma (FPG): 5.5 0.4 mmol/L; glycated haemoglobin (HbA1c): 33 4 mmol/mol, bodyweight: 88.2 14.8 kg, body mass index: 31.1 4.3 kg/m2 ] assigned (n = 49) 55). Estimated difference (ETD) area under curve during was -173 (95% confidence interval -250 -97) mmol/L × min, p < .0001, but wash-out disappeared [ETD 58 (-30 146) .536]. Liraglutide reduced FPG -0.2 (-0.4 -0.1) mmol/L, .018], HbA1c [-2.2 (-3.5 -0.8) .018] bodyweight [-3.9 (-6.2 -1.6) .012]. No change observed. The number prediabetes from 64% 10% vs. 50% [adjusted odds ratio 0.10 (0.03-0.32), .002].Treatment weeks improved tolerance, FPG, pGDM. Progression while markedly reduced, 1-week wash-out, lost.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (55)
CITATIONS (6)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....